MedTech Europe, produced by BBC Story Works: Connecting the Dots video series
NAFLD Patient Pathway Story
Hear from a NAFLD patient about his journey along with the clinical experts who helped develop the pathway
Medscape Education Gastroenterology
Evolution of Diagnosis and Monitoring for Liver Fibrosis
In this Medscape activity, four experts discuss how timely identification of patients at risk of progression using non-invasive diagnostic tests is crucial
Dr. Ankur Srivastava
Consultant Gastroenterologist and Hepatologist
Southmead Hospital, North Bristol Trust
Non-invasive tests can help reduce unnecessary referrals in patients with NAFLD
Dr. Arun J. Sanyal
Professor, Gastroenterology, Hepatology and Nutrition
Virginia Commonwealth University
The need for non-invasive testing in liver fibrosis assessment
*The Enhanced Liver Fibrosis (ELF™) Test kit is not available for sale in the U.S. Product availability may vary from country to country and is subject to varying regulatory requirements.
†In the U.S., the ELF Testing Service is available from Siemens Healthcare Laboratory, LLC (SHL), a CLIA-certified laboratory located in Berkeley, Calif. The ELF Testing Service, including the establishment of performance characteristics, was developed by SHL. The ELF Test has not been cleared or approved by the U.S. Food and Drug Administration. SHL is regulated under CLIA as qualified to perform high complexity testing. The ELF Test is used for clinical purposes and should not be regarded as investigational use only or research use only.